Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need
Sensorion and EVEON Collaborating to Develop an Injection System. (Credit: Reimund Bertrams auf Pixabay)
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and EVEON, designer and manufacturer of custom medical devices for the preparation and delivery of drugs, announce they have been collaborating to design and develop an injection system for the delivery of Sensorion’s gene therapy products to the inner ear, including OTOF-GT product candidate.
Therapies for treating genetic hearing loss are often challenging due to the need for delivery into the inner ear, a very small and delicate organ embedded in the temporal bone. As part of the collaboration, EVEON and Sensorion have been exploring ways to optimise the delivery of gene therapies for improved efficacy and potential patient experience which supports Sensorion’s gene therapy programs development.
“We are really pleased to have been working with ENT surgeons and EVEON to develop an injection system for the safe and effective delivery of our gene therapy candidates,” said Geraldine Honnet, MD, Chief Medical Officer of Sensorion. “Our delivery system is intended to allow the delivery of Sensorion’s gene therapy product candidates into the inner ear with the aim of restoring hearing in patients suffering from hereditary monogenic forms of deafness. Effective and safe administration is critical for gene therapies and we need to ensure an optimal route of injection.”
“At EVEON, we are thrilled to be working with Sensorion, a leader in hearing therapeutics,” said Vincent Tempelaere, Chief Executive Officer at EVEON. “This new project demonstrates the capabilities of our respective technology platforms and enables our teams to work effectively to provide tailor-made solutions for the delivery of new gene therapies.”
Sensorion is pursuing two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by mutations of the gene encoding for otoferlin, and hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
Source: Company Press Release